Sale of AgeX subsidiary will help support development of BioTime’s core programs Balance owed for remaining portion of transaction totals $21.6 million ...
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today ...
BioTime will report earnings from Q4 on March 7. Analysts predict BioTime will release losses per share of $0.043. Go here to track BioTime stock price in real-time on Markets Insider. BioTime ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback